The asteroid Bennu continues to provide new clues to scientists’ biggest questions about the formation of the early solar system and the origins of life. As part of the ongoing study of pristine samples delivered to Earth by NASA’s OSIRIS-REx…
A leading thinktank has warned Rachel Reeves that tight government spending and higher taxes will restrict consumer expenditure, despite it predicting the UK economy will grow at a faster pace than France, Germany and Italy next year.
Analysts at the Organisation for Economic Cooperation and Development (OECD) said the government’s ongoing “fiscal consolidation” – meaning higher taxes and reduced government spending – would act as a “headwind” to the UK economy, with “past tax and spending adjustments weighing on household disposable income and slowing consumption”.
The Paris-based organisation predicted that the UK economy would expand by 1.2% next year, while the big three eurozone economies would each fail to reach 1%.
Offering a boost to Reeves after she faced calls to resign after the budget, the UK’s growth rate was upgraded from a previous forecast of 1% for next year. However, that represents a slowdown from the 1.4% growth predicted for this year, unchanged from the last forecast three months ago.
The chancellor – who has put an emphasis on growing the UK economy – announced £26bn worth of tax rises in last week’s budget, with measures including a freeze on income tax thresholds that will leave 1.7 million people paying more, taking the tax burden to an all-time high, according to the Office for Budget Responsibility (OBR).
Separately, the OECD said the US economy would grow by 1.7% next year, down from 2% this year and 2.4% in 2024, in a blow to Donald Trump’s efforts to increase growth by restricting imports and reducing regulations on big industries.
In a report that highlighted how a flurry of activity this year to cope with Trump’s tariffs had given a temporary lift to many economies, the OECD said there would be a return to lower, stagnant rates of expansion across much of the industrialised world.
The UK, like most industrialised countries, is expected to reduce interest rates as inflation is predicted to gradually return to a 2% target by mid-2027. The report predicts there will be two more reductions in rates, from 4% now to 3.5% in the second quarter of 2026, but this will mark the end of rate cuts.
The chancellor welcomed the prospect of higher growth and lower inflation. She said: “Last week my budget cut waiting lists, cut borrowing and debt and cut the cost of living. Less than a week later, the OECD has upgraded our growth and cut its forecast for inflation next year.”
The UK’s economic establishment was rocked on Monday by the resignation of Richard Hughes, the chair of the OBR, which provides the Treasury with independent forecasts of the economic outlook and government finances.
Hughes quit after a report said the leadership of the OBR should take responsibility for information about the budget being accessed before the chancellor’s speech, breeching a longstanding protocol. Hughes was also in the midst of a dispute with Reeves over whether she had misled the public about the state of the public finances based on private briefings by the OBR.
Most governments are expected to struggle to accelerate growth next year while they impose tight spending controls and restrict borrowing levels, limiting their ability to increase investment and raise living standards.
skip past newsletter promotion
after newsletter promotion
Mathias Cormann, the OECD secretary general, described the return of low growth as a mark of resilience amid global uncertainty about trade. However, he said there were concerns about low levels of productivity across the OECD’s 38 member countries, which also include Vietnam, Mexico, Canada and Costa Rica.
The OECD report said: “The global economy has been resilient this year, despite concerns about a sharper slowdown in the wake of higher trade barriers and significant policy uncertainty. Activity has held up thanks to front-loading of production and trade, strong AI-related investment and supportive fiscal and monetary policies.
“Yet, global trade growth moderated in the second quarter of this year, and we expect higher tariffs to gradually feed through to higher prices, reducing growth in household consumption and business investment. Labour markets are still relatively tight, but are showing signs of easing, as job openings have fallen back to their pre-pandemic levels of 2019.”
In line with most other international forecasters, the OECD said global economic growth would slow from 3.3% in 2024 to 3.2% in 2025 and 2.9% in 2026, followed by a small rebound to 3.1% in 2027.
In October the International Monetary Fund said global growth was projected to slow from 3.3% in 2024 to 3.2% in 2025 and 3.1% in 2026.
In an apparent rebuke to Trump, Cormann said: “Constructive dialogue between countries is central to ensure a lasting resolution to trade tensions and improve the economic outlook.”
KACHEHEMBE, Congo — Measles vaccines have arrived in a rebel-held area of eastern Congo nearly a year after a deadly outbreak of the highly contagious disease began.
The seizure of parts of the region early this year by Rwanda-backed M23 rebels…
Christchurch [New Zealand], December 2 (ANI): A half-century from Kane Williamson was the highlight of New Zealand’s innings as West Indies took wickets at regular intervals on day one of the first Test at Christchurch on Tuesday.
The first step on the Moon was one of humanity’s most exciting accomplishments. Now scientists are planning return trips – and dreaming of Mars beyond.
Next year, Nasa’s Artemis II mission will send four astronauts to fly around the…
Simply sign up to the UK banks myFT Digest — delivered directly to your inbox.
Barclays’ chief executive has suggested that fintech rival Revolut has benefited from its lack of a full UK banking licence, with the fast-growing digital start-up not required to meet some “very important consumer obligations” imposed on traditional lenders.
CS Venkatakrishnan told the FT Global Banking Summit on Tuesday that fintechs had “really laid down the gauntlet to the banks in terms of the quality of services they provide”.
However, he suggested that banks were not operating on a level playing field with digital challengers such as Revolut.
“There is another side of it, which is that they don’t have a full banking licence in the UK, so they are free from some of the very important consumer obligations that we have to fulfil to society,” said Venkatakrishnan.
“I think we should continue to operate with our standards, with our integrity, with our regulation. If we can marry them, we will be happy,” he added.
Revolut secured a $75bn valuation in a fundraising round that concluded last week, briefly making it worth more than Barclays.
The banking start-up has become one of Europe’s most valuable fintechs, helped by a boom in demand for its crypto services. Revolut has 65mn customers globally, with 12mn in the UK.
Paul Thwaite, the NatWest chief executive, said in a separate interview at the summit that he was not concerned about being overtaken in valuation terms by Revolut, which he called a “very different business” compared with “a NatWest or a Barclays”.
“I don’t lose sleep thinking about market capitalisation. I lose sleep thinking about how we have got the best possible product and proposition to deliver to our clients,” he said.
Thwaite added: “Companies like Revolut have raised the bar in terms of the retail proposition so that is the lens I am looking at it through. What are they doing for their customers? What do we think we are doing better than what they are doing? What do I think we need to be better at?”
UK regulators are yet to award Revolut a full banking licence, capping the deposits it can take in and limiting its ability to lend, in part because of the rapid growth of its overseas operations.
Revolut said: “As a UK payment service provider, Revolut abides by the same regulatory and consumer protection standards as any traditional bank or other financial institution.”
Venkatakrishnan said that Barclays took on its consumer obligations “willingly and happily”.
He also commended UK chancellor Rachel Reeves after last week’s Budget for focusing on growth and building a greater fiscal buffer into the public finances.
“On balance, [the Budget] is a very good job. It is a good job that gives this government the room to take the next steps to promote growth and productivity, which is really what is needed,” he said.
Last week, Barclays announced it would be boosting investment in the UK by £45bn over the next three years.
“These are not small amounts and this reflects our confidence [in the UK],” said Venkatakrishnan.
China’s experimental Shijian-21 and Shijian-25 satellites recently separated in geosynchronous orbit and reportedly conducted on-orbit refueling tests. The two satellites had been docked with one another for months.
Data being presented showcases AbbVie’s breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of difficult-to-treat blood cancers
NORTH CHICAGO, Ill., Dec. 2, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie’s blood cancer portfolio will be featured in multiple oral and poster presentations including investigational compounds etentamig (ABBV-383) and PVEK (pivekimab sunirine), as well as approved therapies EPKINLY® (epcoritamab-bysp) and VENCLEXTA® (venetoclax).
“These ASH presentations reinforce AbbVie’s leadership in advancing the potential next wave of blood cancer innovation, with clinical data that highlight our commitment to raising the standard of care,” said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology at AbbVie. “The data also highlights the depth and diversity of our pipeline and portfolio of approved medicines spanning across T-cell engagers, BCL-2 Inhibitors and ADCs, all designed to address the heterogeneity of blood cancers for a range of patients.”
Key data from epcoritamab, venetoclax-based treatments, etentamig and PVEK to be highlighted as oral presentations demonstrate promising efficacy, durable responses, and safety profiles across multiple hematologic malignancies and lines of therapy:
Fixed-Duration epcoritamab (CD20×CD3 Bispecific T-Cell Engager) in combination with rituximab and lenalidomide (R2) in Relapsed or Refractory FL
Results from the randomized phase 3 trial EPCORE FL-1 (NCT05409066) of fixed-duration epcoritamab, in combination with R2 for patients with relapsed or refractory (R/R) FL (n=243) demonstrate significantly superior progression-free survival (PFS) and overall response rates (ORR) compared to standard of care R2 (n=245).1
The study showed that treatment with epcoritamab + R2 (E+R2) reduced the risk of disease progression or death by 79% compared to standard of care R2, with significantly longer PFS in patients treated with E+R2 vs. those treated with R2 (hazard ratio [HR] 0.21; 95% CI: 0.13, 0.33; P<.0001). A preplanned interim analysis was conducted after the first 232 patients achieved 12 months of follow-up post-randomization, and the ORR was significantly improved in patients treated with E+R2 (95.7% [95% CI: 90.2, 98.6]) vs R2 (81.0% [95% CI: 72.7, 87.7]; P<.0001.1
Among patients who were treated with E+R2, 74.5% achieved a complete response (CR) (n=95% CI: 68.5, 79.8) compared to a 43.3% CR rate among patients treated with R2 (n=95% CI: 37.0, 49.7).1
Grade 3/4 treatment emergent adverse events (TEAEs) were reported in 88.1% of patients receiving E+R2 vs 62.2% with R2, the difference being primarily driven by higher rates of neutropenia (66.3% vs 37.8%) and infections (29.2% vs 13.4%).1 In the E+R2 group, CRS events were at a low grade, and all resolved eventually.1 Recently, EPKINLY in combination with R2 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with R/R FL.2
Fixed-Duration Venetoclax (BCL-2 Inhibitor) Regimens in Previously Untreated CLL
Interim data will be showcased from the randomized, Phase 3 CLL17 trial (NCT04608318) conducted and presented by the German CLL Study Group (GCLLSG) comparing continuous ibrutinib (I) monotherapy (n=301) to fixed-duration venetoclax plus obinutuzumab (VO; n=303) and venetoclax plus ibrutinib (VI; n=305) for patients with previously untreated CLL.3 The study was designed to test non-inferiority of VO vs I and VI vs I.3
After a median follow-up of 34.2 months, the study met non-inferiority endpoints for the VO arm compared to I arm (HR 0.87, type-I-error adjusted CI [98.3%] 0.54-1.41) and for VI arm compared to I arm (HR 0.84, type-I-error adjusted CI [98.0%] 0.53-1.32).3 The 3-year PFS for VO, I and IV arms were 81.1%, 81.0% and 79.4% respectively.3
The most frequent adverse events (AEs) were infections and infestations (VO: 76.3%, VI: 80.2%, I: 79.9%), gastrointestinal disorders (VO: 59.7%, VI: 74.3%, I: 63.4%), and blood and lymphatic system disorders (VO: 59.0%, VI: 42.9%, I: 28.5%).3
Venetoclax plus ibrutinib is an investigational combination not approved by the FDA.
Etentamig (Bispecific T-Cell Engager) in R/R MM and AL
Results from a Phase 1b multi-arm, open-label study evaluating etentamig, a BCMAxCD3 bispecific T-cell engager, (NCT05259839) combined with pomalidomide and dexamethasone (POM+DEX) in 85 heavily pretreated (at least 3 prior lines of therapy) R/R multiple myeloma patients will be presented.4
Preliminary data from the dose escalation portion of the study (n=82) highlight that etentamig in combination with POM+DEX achieved an ORR of 81% and a very good partial response or better (≥VGPR) of 72% at median follow-up of 23 months (range: 1-33 months).4 In this heavily pretreated population, duration of response (DoR) were not reached at time of analysis.
Most common grade 3/4 AEs were neutropenia (78%), anemia (28%) and thrombocytopenia (22%).4 Overall, these data support further exploration of the regimen in a randomized Phase 3 study.4
Additional preliminary data from the dose escalation study with etentamig monotherapy in R/R light chain AL will be showcased as an oral presentation. (NCT06158854)
PVEK (Antibody Drug Conjugate) in Newly Diagnosed AML
PVEK is a first-in-class antibody-drug conjugate comprised of a high-affinity anti-CD123 antibody and an indolinobenzodiazepine pseudodimer (IGN) payload. An oral presentation will showcase data from the dose expansion part of an open-label Phase 1b/2 study of PVEK combined with venetoclax and azacitidine (VEN + AZA) in newly diagnosed, CD123-positive AML patients (n=49) who are unfit for intensive chemotherapy (NCT04086264).5 The results show high CR rates of 63.3% with PVEK+VEN+AZA.5 The most common TEAEs (any grade) were neutropenia and thrombocytopenia (both at 69%), constipation (61%) and peripheral edema (51%).5 These data highlight the need to further evaluate this regimen in a randomized trial.5
A Biologics License Application (BLA) for PVEK was recently submitted to the FDA seeking approval for patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare blood cancer.6
Details on key presentations at the ASH 2025 Congress are available below and the full abstracts are available here:
Title
Date/Time
Session
Abstract / Presentation Number
Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial
Saturday, December 6, 10:15 AM – 10:30 AM ET
Oral Abstract Session
Presentation ID 64
Room
OCCC – Tangerine Ballroom F2
Session 629: Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Overcoming Barriers in Frontline Therapy: Bispecific Antibodies for Older Adults with DLBCL
3828
Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study
Saturday, December 6, 02:00 – 02:15 PM ET
Oral Abstract Session
Presentation ID 247
Room
OCCC – West Hall D1
Session 654: Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma
1875
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)
Saturday, December 6, 02:00 – 02:15 PM ET
Oral Abstract Session
Presentation ID 235
Room OCCC – Valencia Room W415BC
Session 637: Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes
13272
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial
Sunday, December 7, 09:45 AM – 10:00 AM ET
Oral Abstract Session
Presentation ID 464
Room
OCCC – West Hall D2
Session 623: Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological – Immunotherapies for Follicular Lymphoma
11119
Primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma
Sunday, December 7, 10:15 – 10:30 AM ET
Oral Abstract Session
Presentation ID 466
Room
OCCC – West Hall D2
Session 623: Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological – Immunotherapies for Follicular Lymphoma
244
Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial
Sunday, December 7, 02:05 – 02:20 PM ET
Marquee Sessions
Presentation ID 1
OCCC – West Hall D2
Plenary Scientific Session
2071
Results from paradigm – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
Sunday, December 7, 03:45 – 04:00 PM ET
Marquee Sessions
Presentation ID 6
Room
OCCC – West Hall D2
Session: Plenary Scientific Session
8236
Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis
Sunday, December 7, 04:45 – 05:00 PM ET
Oral Abstract Session
Presentation ID 692
OCCC – Tangerine Ballroom F1
Session 652: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: New therapies and treatment goals for AL amyloidosis
10869
Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia
Sunday, December 7, 05:00 PM – 05:15 PM ET
Oral Abstract Session
Presentation ID 651
Room
OCCC – Chapin Theater (W320)
Session 616: Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and chemotherapy combinations in AML
2524
Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial
Sunday, December 7, 05:15 – 05:30 PM ET
Oral Abstract Session
Presentation ID 682
Room OCCC – W224ABEF
Session 642: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL
2333
Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial
Monday, December 8, 11:00 – 11:15 AM ET
Oral Abstract Session
Presentation ID 795
Room OCCC – W224ABEF
Session 642: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: MRD Guided Therapy and Emergence of Resistance
7495
Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial
Monday, December 8, 04:30 – 04:45 PM ET
Oral Abstract Session
Presentation ID 1015
Room
OCCC – Tangerine Ballroom F1
Session 629: Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Improving Outcomes in Rare Large Cell Lymphomas
2683
Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial
Monday, December 8, 04:30 PM – 04:45 PM ET
Oral Abstract Session
Presentation ID 1017
Room OCCC – Tangerine Ballroom F1
Session 629: Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Improving Outcomes in Rare Large Cell Lymphomas
7534
Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma
Monday, December 8, 06:00 PM – 08:00 PM EST
Poster Abstract Session
Presentation ID 5513
Room
OCCC – West Halls B3-B4
Session 629: Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III
7543
Etentamig (ABBV-383) and PVEK are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies. EPKINLY®(epcoritamab-bysp)and VENCLEXTA®(venetoclax) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.
EPKINLY®/TEPKINLY® (epcoritamab) is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
VENCLEXTA®/VENCLYXTO® (venetoclax) is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.
Additional information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/.
U.S. Prescribing Information for AbbVie Medicines
EPKINLY® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION
What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with:
certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory), after 2 or more treatments.
EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.
follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
follicular lymphoma (FL) that has come back or that did not respond after receiving 2 or more treatments.
It is not known if EPKINLY is safe and effective in children.
Important Warnings—EPKINLY can cause serious side effects, including:
Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.
People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.
People with follicular lymphoma (FL) may need to be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS.
Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.
EPKINLY can cause other serious side effects, including:
Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.
Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.
Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.
Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.
The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.
The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.
These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.
You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).
Please click here for the Full Prescribing Information and Medication Guide.
VENCLEXTA® (venetoclax) U.S. Uses and Important Safety Information
Uses VENCLEXTA is a prescription medicine used:
to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who: ‒ are 75 years of age or older, or ‒ have other medical conditions that prevent the use of standard chemotherapy.
It is not known if VENCLEXTA is safe and effective in children.
Important Safety Information
What is the most important information I should know about VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.
Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.
Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.
Who should not take VENCLEXTA?
Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.
Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.
Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.
Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:
have kidney or liver problems.
have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
have a history of high uric acid levels in your blood or gout.
are scheduled to receive a vaccine. You should not receive a “live vaccine” before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.
are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA, and you should use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA. If you become pregnant or think you are pregnant, tell your healthcare provider right away.
are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.
What should I avoid while taking VENCLEXTA?
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.
What are the possible side effects of VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Low white blood cell counts (neutropenia). Low white blood cell counts are common with VENCLEXTA, but can also be severe. Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA and may pause dosing.
Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you have a fever or any signs of infection during treatment with VENCLEXTA.
Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.
The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.
The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.
VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for the Full Prescribing Information and Medication Guide.
Globally, prescribing information varies; refer to the individual country product labels for complete information.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
Falchi L, Nijland M, Huang H, et al. Primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma. Abstract 224 presented at the American Society of Hematology Congress 2025. Orlando, Florida.
Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial. Abstract 2071 presented at the American Society of Hematology Congress, 2025. Orlando, Florida.
Voorhees P, D’Souza A, Quach H, et al. Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study. Abstract 1875 presented at the American Society of Hematology Congress, 2025. Orlando, Florida.
Daver N, Advani A, De La Fuente Burguera A, et al. Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia. Abstract 2524 presented at the American Society of Hematology Congress, 2025. Orlando, Florida.
Cazzato G, Capuzzolo M, Bellitti E, et al. Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview. Hematol Rep 2023;15(4):696-706 doi: 10.3390/hematolrep15040070.
DENVER — The Denver Nuggets are concerned about Jamal Murray after the point guard sprained his right ankle during Monday night’s 131-121 loss to the Dallas Mavericks.
